Open an account

Upstream Bio

UPB · NASDAQ

$2.82+$0.02 (+0.71%)TodayMarket closed ·
Prev close $2.80

About UPB

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The company has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

Employees
75
Headquarters
Waltham, Massachusetts
Listed
Oct 11, 2024
Sector
Health Care
Industry
Biotechnology
Website
upstreambio.com

UPB key statistics

Market cap
154.45M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.05M
Volume
1.68M
Open price
$2.79
High today
$3.09
Low today
$2.78
52 Week high
$33.68
52 Week low
$2.74

Upstream Bio (UPB) at a glance

Upstream Bio (UPB) last traded at $2.82, with a market cap of 154.45M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.78 and $3.09. The current price is 1.4% above the day's low and 8.7% below its high.

Volume so far is 1.68M shares, above the average of 1.05M shares a day.

Over the past year Upstream Bio has ranged from $2.74 to $33.68, and now sits 0% of the way up that range.

Upstream Bio met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.73 per share against an estimate of -$0.7687.

The average analyst price target is $34.68, 1129.8% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 6 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 7 analystsAvg $34.68
Low
$15.15
Now
$2.82
High
$78.75

UPB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 9.7% on average.

  1. Q3 FY24: reported -$6.96 per share against an estimate of -$3.72
  2. Q4 FY24: reported -$1.59 per share against an estimate of -$0.5656
  3. Q1 FY25: reported -$0.51 per share against an estimate of -$0.4899
  4. Q2 FY25: reported -$0.74 per share against an estimate of -$0.6186
  5. Q3 FY25: reported -$0.63 per share against an estimate of -$0.7898
  6. Q4 FY25: reported -$0.785 per share against an estimate of -$0.7057
  7. Q1 FY26: reported -$0.75 per share against an estimate of -$0.7811
  8. Q2 FY26: reported -$0.73 per share against an estimate of -$0.7687

UPB news

  • Press releaseGlobe Newswire

    Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

  • Press releaseGlobe Newswire

    Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

  • Vandana Singh

    From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

  • Vandana Singh

    Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

  • Press releaseGlobe Newswire

    Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

  • Vandana Singh

    Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

  • Avi Kapoor

    Crude Oil Gains Over 1%; US Economy Adds 130,000 Jobs In January

  • Vandana Singh

    Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Similar companies

Companies in the same industry as Upstream Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.